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Dysglycemia and Acute Myocardial Infarction
The Role of Echocardiography*
David Verhaert, MD, James D. Thomas, MD
Cleveland, OhioAs the worldwide diabetes epidemic continues un-
abated, physicians and cardiologists involved in the
care of these patients face an increasing burden of
cardiovascular complications attributable to this disease.
The reduced life span in diabetic patients is largely
caused by the consequences of atherosclerosis (1). Not
only do these patients have a risk for future myocardial
infarction (MI) or cardiovascular death that is at least
See page 592
similar to nondiabetic patients with established
coronary artery disease (2–4), diabetes itself also
confers a significant adverse prognosis after acute
coronary syndromes (5). In addition, elevated glu-
cose and glycated hemoglobin levels on admis-
sion—regardless of diabetic status—have repeat-
edly been shown to be independent prognostic
determinants of both in-hospital and long-term
outcome in patients with MI (6–8), as for every 18
mg/dl increase in glucose level there appears to be a
4% increase in mortality in nondiabetic patients (9).
Even though up to 50% of patients hospitalized
with acute MI may develop a hyperglycemic response,
cardiologists are cautioned not to disregard a disturbed
glucometabolic state as simply an epiphenomenon of
acute illness, as shown again in this issue of iJACC in
a study by Høfsten et al. (10). The investigators
evaluated the impact of abnormal glucose metabolism
assessed by an oral glucose tolerance test on outcome
in 203 consecutive patients with acute MI. They then
correlated glucose metabolism with echocardiographic
markers of systolic and diastolic function obtained
shortly after admission (a median of 2 days after the
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Cleveland Clinic, Cleveland, Ohio.diagnosis of acute MI). The investigators were able to
demonstrate a linear relationship between progressive
degrees of glucose intolerance and echocardiographic
indexes of both systolic (ejection fraction) and diastolic
(E/e=, E-wave deceleration time and left atrial size)
function. The indexes used have previously been
shown to carry important prognostic information in
post-infarct patients. The same linear relationship was
seen between dysglycemia and serum N-terminal
pro-B-type natriuretic peptide levels taken on the
same day or shortly after the oral glucose tolerance
test. Subsequently, a clear association was found be-
tween the degree of dysglycemia and outcome in
terms of survival and readmission for congestive heart
failure at a follow-up ranging from 12 to 44 months.
Interestingly, a glucometabolic state during hospital-
ization was still predictive of adverse events after
adjusting for left ventricular (LV) systolic and diastolic
function, leading the investigators to conclude that
prognosis after MI in hyperglycemic patients is not
solely attributable to LV dysfunction.
This is another study highlighting the link be-
tween diabetes and post-MI heart failure. Impor-
tantly, the investigators demonstrate a linear in-
crease in ventricular dysfunction and plasma
N-terminal pro-B-type natriuretic peptide levels
with increasing degrees of dysglycemia. How can
this correlation be explained?
Many conditions specific to the heart in diabetes
can affect post-infarct ventricular function (11,12).
Although the heart uses free fatty acids as its major
energy source under aerobic conditions, glucose oxi-
dation is more efficient, as it requires less oxygen per
molecule of adenosine triphosphate generated. MI
will therefore normally result in enhanced glycogen-
olysis and increased glucose uptake by translocation of
GLUT-4 receptors to the sarcolemma (13). Despite
their hyperglycemia, glucose is relatively unavailable
for diabetics under anaerobic conditions because of
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601epressed levels of the GLUT-4 transporter protein
14), which may lead to more extensive ischemic
amage. Insulinopenia is also associated with in-
reased lipolysis, elevated levels of plasma free fatty
cids, and increased fatty acid oxidation as glycolysis
nd glucose oxidation are suppressed. Free fatty acid
etabolism in this setting may further lead to higher
roduction of lactate and hydrogen ions that have an
dverse effect on cardiac contractility and diastolic
unction and reduce the heart’s threshold for arrhyth-
ias (15). Increased production of oxygen-derived
ree radicals and activation of pro-inflammatory tran-
cription factors may contribute to the impaired mi-
rocirculatory function and platelet hyper-reactivity
hat have been shown to have deleterious effects
uring ischemia and reperfusion in patients with
yperglycemia (12).
Some deficiencies of the current study should be
oted. First, there were some important differences
etween the enrolled normal and dysglycemic pa-
ients. Not only were patients with abnormal glu-
ose metabolism older with more frequent hyper-
ension and atrial fibrillation (factors known to have
profound effect on the diastolic variables that were
easured) but they also less frequently underwent
evascularization, which undoubtedly influenced re-
odeling in this early phase. In addition, we do not
now whether there were differences in infarct size
peak creatine kinase levels), location of the infarct
left anterior descending territory?), transmural ex-
ent of necrosis (or the proportion of ST-segment
levation MIs vs. non–ST-segment elevation MIs)
nd the symptom-to-balloon times. Even though
he investigators adjusted for some of these factors,
t is uncertain whether differences in glucose me-
abolism alone account for the differences in LV
unction seen by echocardiography in their study.
Some methodological issues should also be ac-
nowledged. The major predictor of post-MI heart
ailure in the general population is LV remodeling,
process involving expansion of the infarct-related
egments with subsequent ventricular dilation and
ypokinesis of the noninfarcted regions. Although
jection fraction is a universally recognized param-
ter for systolic function, analysis of end-systolic
olume would have been useful as the issue of
emodeling is clearly of interest in their study.
iven the clear trend in their study for patients with
ysglycemia to more frequently have had prior MIs
potentially underestimated due to the frequent
ilent infarctions in this population), it would have
een interesting to know whether there was a
ifference in end-systolic volumes between* normo- Alycemic and dysglycemic subjects in the early phase
fter MI, as this parameter has been shown to be
losely connected with early management (16).
arger samples of patients hospitalized with acute
I have previously shown that admission glucose
evels are independently associated with a much
reater increase in the risk of death, particularly in
atients without an antecedent history of diabetes
8,9). Høfsten et al. (10) equally suggest that
ifferences in ventricular function alone do not
ccount for the increased rates of heart failure and
ortality commonly observed in diabetics with MI.
an we make that conclusion based on the data
rovided by these investigators? Again, it would
ave been interesting to know why a significant
roportion of patients with diabetes did not have
oronary angiography or revascularization. Besides
ore extensive distal vessel disease, these patients
ay have had more advanced renal insufficiency,
eripheral vascular disease, cerebrovascular disease,
r other types of comorbidities. All these variables
re typically related to the glucometabolic state and
ave important prognostic power but were appar-
ntly not entered in the multivariable analysis.
nfortunately, the investigators did not collect
ollow-up echocardiographic data, which would
ave enabled them to make more definite conclu-
ions about the differential impact of remodeling,
iastolic indexes, and the presence of a (pre-)diabetic
tate on outcome in post-infarct patients. In that
espect, it is interesting to compare this study with the
ata of Carrabba et al. (17), who addressed the very
ame question in a series of 325 consecutive patients
including 45 diabetics) with acute MI, all success-
ully treated with primary angioplasty. Despite
ome animal studies suggesting insulin resistance
nd diabetes cause a greater degree of LV dysfunc-
ion and accelerated LV remodeling after coronary
rtery ligation (18), these investigators did not
bserve a greater propensity for LV remodeling in
atients with diabetes. At 6-month follow-up, sim-
lar patterns of changes in global and regional
ystolic function were found by 2-dimensional
chocardiography in diabetic versus nondiabetic
atients. Carrabba et al. (17) did not perform oral
lucose tolerance testing nor did they use the World
ealth Organization criteria for whole blood glu-
ose levels to account for differences in the degree of
lucometabolic dysregulation. Contrary to the find-
ngs of Høfsten et al., however, these investigators
ound a similar pattern of diastolic dysfunction at
aseline between diabetic and nondiabetic patients.
lthough the presence of heart failure was primarily
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602elated to the development of LV remodeling in the
ondiabetics, diabetes itself (and not remodeling!)
as independently associated with the development
f late-onset heart failure in the diabetic population.
t is noteworthy that in the subgroup of patients
ho developed heart failure at 6 months, diabetic
ubjects demonstrated more advanced diastolic dys-
unction than nondiabetic subjects, suggesting that
he persistence or development of diastolic dysfunc-
ion after the acute phase of acute MI may signif-
cantly contribute to the development of heart
ailure in patients with diabetes.
The mechanisms by which diabetes may trigger a
eries of maladaptive stimuli leading to myocardial
brosis and collagen deposition (even in the absence
f coronary artery disease) are incompletely under-
tood and largely reviewed elsewhere (18,19), but
he findings by both Høfsten et al. (10) and
arrabba et al. (17) suggest that further prospective
tudies evaluating serial changes of diastolic vari-
bles in a larger sample of patients with different
egrees of dysglycemia are needed to better under-
tand the impact of the “diabetic factor” on post-
nfarct heart failure.
Once again, the association between in-hospital
yperglycemia and prognosis has been demon-
trated. The available literature seems to suggest
hat elevated blood glucose with acute MI may in
act be a mediator of adverse outcomes rather than
imply an innocent marker of acute illness, released
y a series of counter-regulatory hormones in re-
ponse to cardiovascular stress (12). However, there
s still much uncertainty with respect to the optimal
anagement of hyperglycemia immediately after
cute MI (20). The concept of a cardioprotective
ocktail (glucose-insulin-potassium [GIK]) to pro-
ote glycolysis, reduce free fatty acid concentra-
ions, and stabilize membranes by restoring potas-
ium influx in ischemic cardiomyocytes has been the
ocus of numerous clinical trials (15). The results of
hese studies have been variable, and therefore GIK
s at present not recommended as a standard ad-
unctive treatment with reperfusion. Likely expla-
ations for the negative results in some of these
rials are the fixed-dose cocktails without adjust-
ents in the amount of intravenous volume or
lucose administered. In those studies, the potential
enefit of GIK may have been offset by the devel-
pment of fluid overload or exacerbation of hyper-
lycemia early in the course of myocardial injury.
Apart from the GIK strategy, there are definitely
number of arguments favoring tight glycemicontrol in the coronary care unit (12). Although a Carget blood glucose level as close as possible to 110
g/dl is sometimes advocated, one should be cau-
ious in extrapolating the results of other trials
howing beneficial effects of aggressive insulin ther-
py in the intensive care unit (21), as patients with
cute MI likely represent a completely different
tudy population. Of concern are 2 observational
tudies that showed an association between the
evelopment of hypoglycemia during hospitaliza-
ion for acute MI and an increased risk of death
22,23). The optimal glycemic control in these
atients after admission is another issue that re-
ains highly uncertain. Two recent large random-
zed trials investigating the effect of intensive glu-
ose lowering in type 2 diabetes patients with
stablished cardiovascular disease or additional car-
iovascular risk factors failed to demonstrate a
ignificant effect on the risk of major macrovascular
vents and even identified an increase in mortality
ith such an approach (24,25). Ongoing trials will
opefully provide additional clarification (26–29).
In the meantime, what is the role of cardiac
maging? Høfsten et al. (10) have shown that the
ink between abnormalities in glucose metabolism
nd cardiac function provides a fruitful area for
uture research. To date, the main echocardio-
raphic findings in patients with diabetes or dia-
etic cardiomyopathy seemed aspecific and rather
nsensitive: evidence of cardiac hypertrophy along
ith some degree of diastolic dysfunction. Some
tudies showed that a decrease in longitudinal
unction detected by tissue Doppler or strain imag-
ng may be a more sensitive sign of early or
ubclinical myocardial dysfunction due to diabetes
30,31). The concept of a linear relationship be-
ween the degree of dysglycemia and the degree of
ardiac dysfunction definitely deserves further at-
ention. Are the current diagnostic capabilities of
chocardiography really accurate enough to detect
mall differences in systolic and diastolic function
etween patients with different degrees of dysgly-
emia (also outside the context of acute MI)? How
o the diastolic characteristics change over time in
ost-infarct patients with different degrees of glu-
ose intolerance? To what extent can we detect the
ffects of optimized glucose control in diabetic
atients with and without coronary artery disease?
hese and other questions remain to be answered.
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